Kyle Detwiler, CEO of Clever Leaves, and Andrés Fajardo, President of Clever Leaves, met with Ruud Helwig, Managing Director Ethypharm Germany, for a strategy meeting in Berlin to coordinate the approach and marketing strategies for the upcoming medical cannabis market entry in early 2022. Ethypharm has signed an exclusive license agreement with Clever Leaves for the distribution of medical cannabis extracts in Germany, the most important European market for medical cannabis.
Just recently, Bloomberg Línea’s President Andrés Fajardo was named one of the 500 Most Influential People in Latin America. This underlines the importance that the launch in Germany has for both parties. Kyle Detwiler said, “Clever Leaves is committed to becoming a leading B2B solution provider in the global cannabis industry by offering customers a pharmaceutical asset-light approach to cannabinoid production in one of the most regulated industries in the world offers. ”Ruud Helwig emphasized that the upcoming change of government in Germany will open up further market opportunities for medical cannabis. “We come at just the right time with our products,” he said.
Clever Leaves will manufacture and supply EU GMP certified medical cannabis extracts sourced from their facilities in Colombia and Portugal. Colombia has the potential to become the world’s largest exporter of cannabis. The products for the manufacture of prescription drugs will be marketed and distributed by Ethypharm in Germany at the beginning of 2022. The portfolio includes high-CBD, high-THC and balanced CBD-THC formulations, which are often prescribed by doctors in Germany for the symptomatic treatment of neurological diseases and chronic pain in palliative situations.